Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Abstract

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed as therapeutics and are a major contributor to neutralizing antibody responses elicited by infection. Here, we describe a deep mutational scanning method to map how all amino-acid mutations in the RBD affect antibody binding and apply this method to 10 human monoclonal antibodies. The escape mutations cluster on several surfaces of the RBD that broadly correspond to structurally defined antibody epitopes. However, even antibodies targeting the same surface often have distinct escape mutations. The complete escape maps predict which mutations are selected during viral growth in the presence of single antibodies. They further enable the design of escape-resistant antibody cocktails-including cocktails of antibodies that compete for binding to the same RBD surface but have different escape mutations. Therefore, complete escape-mutation maps enable rational design of antibody therapeutics and assessment of the antigenic consequences of viral evolution.

Cited by papers we hold 46

• Learning from prepandemic data to forecast viral escape · 2023
  No notice
• Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting · 2023
  No notice
• Fitness effects of mutations to SARS-CoV-2 proteins · 2023
  No notice
• Investigation of target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of COVID-19 in Vietnam · 2022
  Not checked
• SARS-CoV-2 variants of concern surveillance including Omicron using RT-PCR–based genotyping offers comparable performance to whole genome sequencing · 2022
  Not checked
• Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies · 2022
  Not checked
• An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain · 2022
  No notice
• Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons · 2022
  No notice
• Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera · 2022
  No notice
• BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection · 2022
  No notice
• SARS-CoV-2 Omicron variant: recent progress and future perspectives · 2022
  No notice
• Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa · 2022
  No notice
• Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness · 2022
  No notice
• Drivers of adaptive evolution during chronic SARS-CoV-2 infections · 2022
  No notice
• ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies · 2022
  No notice
• Predicting the mutational drivers of future SARS-CoV-2 variants of concern · 2022
  No notice
• Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa · 2022
  No notice
• Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains · 2022
  No notice
• Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models · 2022
  No notice
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice

and 26 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.